Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments
Protease inhibitors are of considerable interest as anticancer agents. Matrix metalloproteinases (MMPs) were the earliest type of proteases considered as anticancer targets. The developments of MMP inhibitors (MMPIs) by pharmaceutical companies can be dated from the early 1980s. Thus far, none of the over 50 MMPIs entering clinical trials have been approved. This work summarizes the reported studies on the structure of MMPs and complexes with ligands and inhibitors, based on which, the authors analyzed the clinical failures of MMPIs in a structural biological manner. Furthermore, MMPs were systematically compared with urokinase, a protease-generating plasmin, which plays similar pathological roles in cancer development; the reasons for the clinical successes of urokinase inhibitors and the clinical failures of MMPIs are discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 14(2022), 1 vom: 29. Jan., Seite 35-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Haili [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.02.2022 Date Revised 10.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2021-0246 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333174062 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333174062 | ||
| 003 | DE-627 | ||
| 005 | 20231225221114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2021-0246 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333174062 | ||
| 035 | |a (NLM)34779649 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Haili |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2022 | ||
| 500 | |a Date Revised 10.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Protease inhibitors are of considerable interest as anticancer agents. Matrix metalloproteinases (MMPs) were the earliest type of proteases considered as anticancer targets. The developments of MMP inhibitors (MMPIs) by pharmaceutical companies can be dated from the early 1980s. Thus far, none of the over 50 MMPIs entering clinical trials have been approved. This work summarizes the reported studies on the structure of MMPs and complexes with ligands and inhibitors, based on which, the authors analyzed the clinical failures of MMPIs in a structural biological manner. Furthermore, MMPs were systematically compared with urokinase, a protease-generating plasmin, which plays similar pathological roles in cancer development; the reasons for the clinical successes of urokinase inhibitors and the clinical failures of MMPIs are discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a inhibitors | |
| 650 | 4 | |a matrix metalloproteinases | |
| 650 | 4 | |a molecular mechanism | |
| 650 | 4 | |a structural biology | |
| 650 | 4 | |a urokinase | |
| 650 | 7 | |a Hydroxamic Acids |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase Inhibitors |2 NLM | |
| 650 | 7 | |a Tissue Inhibitor of Metalloproteinases |2 NLM | |
| 650 | 7 | |a Urokinase-Type Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.73 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinases |2 NLM | |
| 650 | 7 | |a EC 3.4.24.- |2 NLM | |
| 700 | 1 | |a Xu, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Mingdong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 14(2022), 1 vom: 29. Jan., Seite 35-51 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:1 |g day:29 |g month:01 |g pages:35-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2021-0246 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 1 |b 29 |c 01 |h 35-51 | ||